Drug Repurposing in Chemical Genomics: Can We Learn from the Past to Improve the Future?

被引:0
|
作者
Bisson, William H. [1 ]
机构
[1] Oregon State Univ, Environm Hlth Sci Ctr, Dept Environm & Mol Toxicol, Corvallis, OR 97331 USA
关键词
Chemical Genomics; Clinical Phase; Drug; High Throughput Screening; Repurposing; Translational Research; Virtual Ligand Screening; ABANDONED DRUGS; DISCOVERY; CANCER;
D O I
暂无
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
More needs to be done by the private sector to optimize the drug discovery and development pipeline. In addition, significant efforts should also be focused on the understanding of mechanism of diseases, on the characterization of unexplored biochemical pathways and on the validation of new protein targets. Chemical genomics, which uses chemical probes to help understand the complexity of biological systems at the gene and protein levels, has proven in recent years to be an important tool. Experimental and computational chemical genomic screenings have been used by the private sector and recently also by academia and non-profit institutions for drug repurposing or repositioning to find new indications for known drugs. A detailed overview of the current initiatives in drug repurposing, initiated by the major governmental funding agencies around the world is reported. The push towards greater efficiency is encouraging drug repurposing and other techniques in chemical genomics. Finding the best ways to improve translational research and accelerate the regulation of clinical phases means being able to launch safer drugs into the market faster.
引用
收藏
页码:1883 / 1888
页数:6
相关论文
共 50 条
  • [31] Chairman's introduction: What can we expect to learn from genomics?
    Mathers, JC
    PROCEEDINGS OF THE NUTRITION SOCIETY, 2004, 63 (01) : 1 - 4
  • [32] WHAT CAN WE LEARN FROM THE NERVOUS SEQUELAE OF PAST PANDEMICS?
    Honigsbaum, Mark
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2022, 93 (12):
  • [33] How we can learn from analysing trauma in past societies
    Mitchell, Piers D.
    Bendrey, Robin
    INTERNATIONAL JOURNAL OF OSTEOARCHAEOLOGY, 2022, 32 (04) : 721 - 721
  • [34] SKELETON OF "THE IRISH GIANT" We cannot change the past, but we can learn from it
    Smith, Martin
    Knuesel, Christopher
    Chamberlain, Andrew
    Mitchell, Piers D.
    BMJ-BRITISH MEDICAL JOURNAL, 2012, 344
  • [35] We can learn a lot from drug adverse effects
    Mandell, Brian F.
    CLEVELAND CLINIC JOURNAL OF MEDICINE, 2018, 85 (09) : 654 - 655
  • [36] What can we learn from drug marketing efficiency?
    Kao, David P.
    BRITISH MEDICAL JOURNAL, 2008, 337
  • [37] How can we improve cervical cancer screening: What can we learn from mistakes?
    Grigore, Mihaela
    Nandrean, Alexandru
    Gafitanu, Dumitru
    BULLETIN DU CANCER, 2020, 107 (03) : 322 - 327
  • [38] What can we learn about chemical tractability of drug targets from known PDB structures?
    Gao, Ying-Duo
    Sheridan, Robert P.
    Maiorov, Vladimir
    Holloway, M. Kate
    Cornell, Wendy
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 242
  • [39] Sustainability: What can we learn from the past? (Reprinted from Illinois Steward)
    McIsaac, G
    JOURNAL OF SUSTAINABLE AGRICULTURE, 1996, 9 (01): : 3 - 8
  • [40] From the past to the future: what we learn from China’s 2020 Census
    Zhenzhen Zheng
    China Population and Development Studies, 2021, 5 (2) : 101 - 106